These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 15470221

  • 21. [YVDD is the primary symbol of gene mutation in hepatitis B patients treated with lamivudine].
    Tian Y, Du SC, Zhang R, Wei L, Chen Y, Han JD.
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jun; 13(6):455-6. PubMed ID: 15975283
    [No Abstract] [Full Text] [Related]

  • 22. Multidrug resistance after lamivudine therapy for chronic hepatitis B.
    Sarrecchia C, Volpi A, Sordillo P, Andreoni M.
    Int J Infect Dis; 2009 May; 13(3):e133-4. PubMed ID: 18990599
    [No Abstract] [Full Text] [Related]

  • 23. Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications.
    Hui CK, Leung N, Shek WH, Zhang HY, Luk JM, Poon RT, Lo CM, Fan ST, Lau GK, Hong Kong Liver Fibrosis Study Group.
    J Clin Gastroenterol; 2008 May; 42(5):533-8. PubMed ID: 18344885
    [Abstract] [Full Text] [Related]

  • 24. Hepatitis B e Antigen--the dangerous endgame of hepatitis B.
    Liang TJ, Ghany M.
    N Engl J Med; 2002 Jul 18; 347(3):208-10. PubMed ID: 12124411
    [No Abstract] [Full Text] [Related]

  • 25. Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment.
    Sherman M.
    Cleve Clin J Med; 2009 May 18; 76 Suppl 3():S6-9. PubMed ID: 19465708
    [Abstract] [Full Text] [Related]

  • 26. Effects of HBV gene variations on disease development and antiviral therapy for patients with chronic hepatitis B.
    Chen JY, Wang LW, Sun XM, Gong ZJ.
    Hepatobiliary Pancreat Dis Int; 2005 Aug 18; 4(3):393-7. PubMed ID: 16109523
    [Abstract] [Full Text] [Related]

  • 27. [Individual therapy for the patients with YMDD mutation in HBV by lamivudine].
    Liu Z.
    Zhonghua Gan Zang Bing Za Zhi; 2003 Sep 18; 11(9):558. PubMed ID: 14552722
    [No Abstract] [Full Text] [Related]

  • 28. Hepatitis B therapy: the plot thickens.
    Malik AH, Lee WM.
    Hepatology; 1999 Aug 18; 30(2):579-81. PubMed ID: 10421673
    [No Abstract] [Full Text] [Related]

  • 29. [Strategies for the prevention of hepatocellular carcinoma in the context of chronic viral hepatitis].
    Schott E, Bergk A, Berg T.
    Z Gastroenterol; 2008 Jan 18; 46(1):69-80. PubMed ID: 18188819
    [Abstract] [Full Text] [Related]

  • 30. [Therapy of chronic hepatitis B. Tenofovir--first choice in current EASL guidelines].
    MMW Fortschr Med; 2009 May 28; 151(22):38-9. PubMed ID: 19526965
    [No Abstract] [Full Text] [Related]

  • 31. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements.
    Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma.
    J Gastroenterol Hepatol; 2010 Apr 28; 25(4):657-63. PubMed ID: 20492323
    [Abstract] [Full Text] [Related]

  • 32. Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B.
    Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kobayashi M, Akuta N, Hosaka T, Sezaki H, Yatsuji H, Kawamura Y, Kobayashi M, Kumada H.
    J Med Virol; 2007 Sep 28; 79(9):1286-92. PubMed ID: 17607775
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K, Takehara T, Kato M, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N.
    J Infect Dis; 2008 Oct 15; 198(8):1150-8. PubMed ID: 18713056
    [Abstract] [Full Text] [Related]

  • 35. [Lamivudine treatment for hepatitis B].
    Lamivudine Clincal Practice Group.
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jul 15; 12(7):425-8. PubMed ID: 15487066
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
    Liaw YF.
    Antivir Chem Chemother; 2001 Jul 15; 12 Suppl 1():67-71. PubMed ID: 11594691
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Observation on the therapeutic effect of Lamivudin on chronic hepatitis B].
    Wen X, Li X, Xie H, Chen N, Zeng W, Ru H, Cui X, Tang Z.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Dec 15; 16(4):395-7. PubMed ID: 12665918
    [Abstract] [Full Text] [Related]

  • 40. [Detection of YMDD motif mutations in lamivudine-untreated patients with chronic hepatitis B].
    Yan MH, Zhang C, Ling Q, Zhou RF.
    Zhonghua Gan Zang Bing Za Zhi; 2003 Jul 15; 11(7):430-1. PubMed ID: 12890351
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.